Inhibitors of cyclic nucleotide phosphodiesterase 3 and 5 as therapeutic agents in heart failure

Expert Opinion on Investigational Drugs

Volumn 15, Issue 7, 2006, Pages 733-742

  Stehlik, Josef ^a,b   Movsesian, Matthew A ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b Department of Medicine ^*  (United States)

Author keywords

Cyclic AMP; Cyclic GMP; Cyclic nucleotide phosphodiesterase; Heart failure; Inotropy; Myocardium; Phosphodiesterase inhibitor; Vasodilation

Indexed keywords

3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARDIOTONIC AGENT; CGMP BINDING, CGMP SPECIFIC 3',5' CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CGMP-BINDING, CGMP-SPECIFIC 3',5'-CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; CYCLIC AMP; CYCLIC AMP DEPENDENT PROTEIN KINASE; CYCLIC GMP; CYCLIC GMP PHOSPHODIESTERASE; ISOENZYME; NEW DRUG; PHOSPHODIESTERASE III; PHOSPHODIESTERASE INHIBITOR; PROTEIN KINASE B; VASODILATOR AGENT;

ANIMAL; CLASSIFICATION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY BLOOD FLOW; DRUG ANTAGONISM; DRUG COMBINATION; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVATION; ENZYMOLOGY; FORECASTING; HALF LIFE TIME; HEART MUSCLE CELL; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LUNG CIRCULATION; METABOLISM; MULTICENTER STUDY; PHOSPHORYLATION; PHYSIOLOGY; PROSPECTIVE STUDY; PROTEIN PROCESSING; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RAT; REVIEW; TREATMENT OUTCOME; VASCULAR SMOOTH MUSCLE;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; 3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADRENERGIC BETA-ANTAGONISTS; ANIMALS; CARDIOMYOPATHY, HYPERTROPHIC; CARDIOTONIC AGENTS; CORONARY CIRCULATION; CYCLIC AMP; CYCLIC AMP-DEPENDENT PROTEIN KINASES; CYCLIC GMP; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; ENZYME ACTIVATION; FORECASTING; HALF-LIFE; HEART FAILURE, CONGESTIVE; HUMANS; HYPERTENSION, PULMONARY; ISOENZYMES; MULTICENTER STUDIES; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, CARDIAC; PHOSPHODIESTERASE INHIBITORS; PHOSPHORYLATION; PROSPECTIVE STUDIES; PROTEIN PROCESSING, POST-TRANSLATIONAL; PROTO-ONCOGENE PROTEINS C-AKT; PULMONARY CIRCULATION; RANDOMIZED CONTROLLED TRIALS; RATS; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 33747172010     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.15.7.733     Document Type: Review

References (104)

1. CONTI M, JIN SL: The molecular biology of cyclic nucleotide phosphodiesterases. Prog. Nucleic Acid Res. Mol. Biol. (1999) 63:1-38.
2. MOVSESIAN MA: β-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. J. Am. Coll. Cardiol. (1999) 34(2):318-324.
3. CHOI YH, EKHOLM D, KRALL J et al.: Identification of a novel isoform of the cyclic-nucleotide phosphodiesterase PDE3A expressed in vascular smooth-muscle myocytes. Biochem. J. (2001) 353(Part 1):41-50. (Pubitemid 32094598)
4. m, cGMP-inhibited cAMP phosphodiesterase in mammalian myocardium. Biochem. Biophys. Res. Commun. (1993) 190(2):516-521.
5. WECHSLER J, CHOI YH, KRALL J, AHMAD F, MANGANIELLO VC, MOVSESIAN MA: Isoforms of cyclic nucleotide phosphodiesterase PDE3A in cardiac myocytes. J. Biol. Chem. (2002) 277(41):38072-38078. • Identifies three isoforms of PDE3 localised to different intracellular compartments of human myocardium.
6. HAMBLETON R. KRALL J, TIKISHVILI E et al.: Isoforms of cyclic nucleotide phosphodiesterase PDE3 and their contribution to camp hydrolytic activity in subcellular fractions of human myocardium. J. Biol. Chem. (2005) 280(47):39168-39174. • Experimental data on catalytic activity and inhibitor sensitivity of three PDE3 isoforms and their contribution to compartmental cAMP metabolism in human myocardium.
7. 2+ pump of sarcoplasmic reticulum. Nature (1989) 342(6245):90-92.
8. SIMMERMAN HK, JONES LR: Phospholamban: protein structure, mechanism of action, and role in cardiac function. Physiol. Rev. (1998) 78(4):921-947. (Pubitemid 28491945)
9. SEILER S, WEGENER AD, WHANG DD, HATHAWAY DR, JONES LR: High molecular weight proteins in cardiac and skeletal muscle junctional sarcoplasmic reticulum vesicles bind calmodulin, are phosphorylated, and are degraded by Ca2+-activated protease. J. Biol. Chem. (1984) 259(13):8550-8557. (Pubitemid 14090617)
10. TAKASAGO T, IMAGAWA T, SHIGEKAWA M: Phosphorylation of the cardiac ryanodine receptor by cAMP-dependent protein kinase. J. Biochem. (Tokyo) (1989) 106(5):872-877. (Pubitemid 19285912)
11. 2+ channels due to phosphorylation by cAMP-dependent protein kinase. Nature (1993) 364(6434):240-243.
12. LIU H, MAURICE DH: Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP. Br. J. Pharmacol. (1998) 125(7):1501-1510. (Pubitemid 28548563)
13. TILLEY DG, MAURICE DH: Vascular smooth muscle cell phosphodiesterase (PDE) 3 and PDE4 activities and levels are regulated by cyclic AMP in vivo. Mol. Pharmacol. (2002) 62(3):497-506. (Pubitemid 36329367)
14. CORBIN J, RANNELS S, NEAL D et al.: Sildenafil citrate does not affect cardiac contractility in human or dog heart. Curr. Med. Res. Opin. (2003) 19(8):747-752. (Pubitemid 37466145)
15. FRANCIS S.H, NOBLETT BD, TODD BW, WELLS JN, CORBIN JD: Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase. Mol. Pharmacol. (1988) 34(4):506-517. (Pubitemid 18253388)
16. BAIM DS, McDOWELL AV, CHERNILES et al.: Evaluation of a new bipyridine inotropic agent-milrinone-in patients with severe congestive heart failure. N. Engl. J. Med. (1983) 309(13):748-756.
17. BENOTTI JR, GROSSMAN W, BRAUNWALD E, DAVOLOS DD, ALOUSI AA: Hemodynamic assessment of amrinone. A new inotropic agent. N. Engl. J. Med. (1978) 299(25):1373-1377. (Pubitemid 9092478)
18. JASKI BE, FIFER MA, WRIGHT RF, BRAUNWALD E, COLUCCI WS: Positive inotropic and vasodilator actions of milrinone in patients with severe congestive heart failure. Dose-response relationships and comparison to nitroprusside. J. Clin. Invest. (1985) 75(2):643-649. (Pubitemid 15142075)
19. SINOWAY LS, MASKIN CS, CHADWICK B, FORMAN R, SONNENBLICK EH, LE JEMTEL TH: Long-term therapy with a new cardiotonic agent, WIN 47203: drug-dependent improvement in cardiac performance and progression of the underlying disease. J. Am. Coll. Cardiol. (1983) 2(2):327-331.
20. CUFFE MS, CALIFF RM, ADAMS KF Jr et al.: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. J. Am. Med. Assoc. (2002) 287(12):1541-1547. •• Phase III trial; short-term milrinone failed to improve outcomes in heart failure.
21. PACKER M, CARVER JR, RODEHEFFER RJ et al.: Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N. Engl. J. Med. (1991) 325(21):1468-1475. •• Phase III trial; oral milrinone failed to improve outcomes in heart failure.
22. URETSKY BF, JESSUP M, KONSTAM MA et al.: Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Lack of benefit compared with placebo. Enoximone Multicenter Trial Group. Circulation (1990) 82(3):774-780. (Pubitemid 20316728)
23. FELDMAN AM, BRISTOW MR, PARMLEY WW et al.: Effects of vesnarinone on morbidity and mortality in patients with heart failure. Vesnarinone Study Group. N. Engl. J. Med. (1993) 329(3):149-155. (Pubitemid 23195734)
24. COHN JN, GOLDSTEIN SO, GREENBERG BH et al.: A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N. Engl. J. Med. (1998) 339(25):1810-1816.
25. METRA M: The Studies of Oral Enoximone Therapy in Advanced Heart Failure (ESSENTIAL). European Society of Cardiology 2005 Congress, Stockholm, Sweden (2005). • Phase III trial; low-dose oral enoximone failed to improve outcomes in heart failure.
26. ABRAHAM WT, ADAMS KF, FONAROW GC et al.: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J. Am. Coll. Cardiol. (2005) 46(1):57-64. (Pubitemid 40905130)
27. DING B, ABE J, WEI H et al.: A positive feedback loop of phosphodiesterase 3 (PDE3) and inducible cAMP early repressor (ICER) leads to cardiomyocyte apoptosis. Proc. Natl. Acad. Sci. USA (2005). (Pubitemid 41457131)
28. DING B, ABE J, WEI H et al.: Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: implication in heart failure. Circulation (2005) 111(19):2469-2476. (Pubitemid 40696135)
29. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet (1999) 353(9146):9-13. • This study shows a pro-apoptotic action of PDE3 inhibition in heart muscle.
30. Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet (1999) 353(9169):2001-2007. (Pubitemid 29271744)
31. PACKER M, BRITOW MR, COHN JR et al.: The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N. Engl. J. Med. (1996) 334(21):1349-1355. (Pubitemid 26411743)
32. LOWES BD, TSVETKOVA T, EICHHORN EJ, GILBERT EM, BRISTOW MR: Milrinone versus dobutamine in heart failure subjects treated chronically with carvedilol. Int. J. Cardiol. (2001) 81(2-3):141-149. (Pubitemid 34017432)
33. METRA M, NODARI S, D'ALOIA A et al.: β-blocker therapy influences the hemodynamic response to inotropic agents in patients with heart failure: a randomized comparison of dobutamine and enoximone before and after chronic treatment with metoprolol or carvedilol. J. Am. Coll. Cardiol. (2002) 40(7):1248-1258.
34. HAYES JS, BRUNTON LL, MAYER SE: Selective activation of particulate cAMP-dependent protein kinase by isoproterenol and prostaglandin E1. J. Biol. Chem. (1980) 255(11):5113-5119. (Pubitemid 10015830)
35. MOVSESIAN MA: PDE3 inhibition in dilated cardiomyopathy: reasons to reconsider. J. Cardol. Fail. (2003) 9(6):475-480. (Pubitemid 38055657)
36. 2+ channels by β-adrenergic agonists. Proc. Natl. Acad. Sci. USA (1996) 93(1):295-299.
37. RAPUNDALO ST, SOLARO RJ, KRANIAS EG: Inotropic responses to isoproterenol and phosphodiesterase inhibitors in intact guinea pig hearts: comparison of cyclic AMP levels and phosphorylation of sarcoplasmic reticulum and myofibrillar proteins. Circ. Res. (1989) 64(1):104-111. (Pubitemid 19028508)
38. HAUPTMAN PJ, WOODS D, PRIRZKER MR: Novel use of a short-acting intravenous β blocker in combination with inotropic therapy as a bridge to chronic oral β blockade in patients with advanced heart failure. Clin. Cardiol. (2002) 25(5):247-249. (Pubitemid 34457370)
39. KUMAR A, CHOUDHARY G, ANTONIO C et al.: Carvedilol titration in patients with congestive heart failure receiving inotropic therapy. Am. Heart J. (2001) 142(3):512-515. (Pubitemid 32801637)
40. SHAKAR SF, ABRAHAM WT, GILBERT EM et al.: Combined oral positive inotropic and β-blocker therapy for treatment of refractory class IV heart failure. J. Am. Coll. Cardiol. (1998) 31(6):1336-1340. (Pubitemid 128713123)
41. FRANCIS SH, TURKO IV, CORBIN JD: Cyclic nucleotide phosphodiesterases: relating structure and function. Prog. Nucleic Acid Res. Mol. Biol. (2001) 65:1-52.
42. LINCOLN TM, DEY N, SELLAK H: Invited review: cGMP-dependent protein kinase signaling mechanisms in smooth muscle: from the regulation of tone to gene expression. J. Appl. Physiol. (2001) 91(3):1421-1430. (Pubitemid 32803941)
43. MONTORSI F, SALONIA A, DEHO F et al.: Pharmacological management of erectile dysfunction. BJU Int. (2003) 91(5):446-454. (Pubitemid 36359625)
44. ALDASHEV AA, KOJONAZAROV BK, AMATOV TA et al.: Phosphodiesterase Type 5 and high altitude pulmonary hypertension. Thorax (2005) 60(8):683-687. (Pubitemid 41129068)
45. CHOCKALINGAM A, GNANAVELU G, VENKATESAN S et al.: Efficacy and optimal dose of sildenafil in primary pulmonary hypertension. Int. J. Cardiol. (2005) 99(1):91-95. (Pubitemid 40261030)
46. GHOFRANI HA, VOSWINCKEL R, REICHENBERGER F et al.: Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: a randomized prospective study. J. Am. Coll. Cardiol. (2004) 44(7):1488-1496. • Comparison of haemodynamic effects of three different PDE5 inhibitors in humans.
47. MICHELAKIS E, TYMCHAK W, LIEN D, WEBSTER L, HASHIMOTO K, ARCHER S: Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: comparison with inhaled nitric oxide. Circulation (2002) 105(20):2398-2403. (Pubitemid 34556392)
48. MICHELAKIS ED, TYMCHAK W, NOGA M et al.: Long-term treatment with oral sildenafil is safe and improves functional capacity and hemodynamics in patients with pulmonary arterial hypertension. Circulation (2003) 108(17):2066-2069. (Pubitemid 37337580)
49. WILKINS MR, PAUL GA, STRANGE JW et al.: Sildenafil versus Endothelin Receptor Antagonist for Pulmonary Hypertension (SERAPH) study. Am. J. Respir. Crit. Care Med. (2005) 171(11):1292-1297. (Pubitemid 40740738)
50. GALIE N, GHOFRANI HA, TORBICKI A et al.: Sildenafil citrate therapy for pulmonary arterial hypertension. N. Engl. J. Med. (2005) 353(20):2148-2157. (Pubitemid 41653106)
51. COHEN AH, HANSON K, MORRIS K et al.: Inhibition of cyclic 3′-5′-guanosine monophosphate-specific phosphodiesterase selectively vasodilates the pulmonary circulation in chronically hypoxic rats. J. Clin. Invest. (1996) 97(1):172-179. (Pubitemid 26022592)
52. DERUELLE P, GROVER TR, ABMAN SH: Pulmonary vascular effects of nitric oxide-cGMP augmentation in a model of chronic pulmonary hypertension in fetal and neonatal sheep. Am. J. Physiol. Lung Cell Mol. Physiol. (2005) 289(5):L798-L806. (Pubitemid 41504411)
53. KODAMA H, ADACHI H: Improvement of mortality by long-term E4010 treatment in monocrotaline-induced pulmonary hypertensive rats. J. Pharmacol. Exp. Ther. (1999) 290(2):748-752. (Pubitemid 29344571)
54. LARRUE B, JAILLARD S, LORTHIOIR M et al.: Pulmonary vascular effects of sildenafil on the development of chronic pulmonary hypertension in the ovine fetus. Am. J. Physiol. Lung Cell Mol. Physiol. (2005) 288(6):L1193-L1200. (Pubitemid 40695446)
55. OKA M: Phosphodiesterase 5 inhibition restores impaired ACh relaxation in hypertensive conduit pulmonary arteries. Am. J. Physiol. Lung Cell Mol. Physiol. (2001) 280(3):L432-L435. (Pubitemid 32473192)
56. PAUVERT O, BONNET S, ROUSSEAU E, MARTHAN R, SAVINEAU JP: Sildenafil alters calcium signaling and vascular tone in pulmonary arteries from chronically hypoxic rats. Am. J. Physiol. Lung Cell Mol. Physiol. (2004) 287(3):L577-L583. (Pubitemid 39095914)
57. SEBKHI A, STRANGE JW, PHILLIPS SC, WHARTON J, WILKINS MR: Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation (2003) 107(25):3230-3235. (Pubitemid 36793096)
58. WEIMANN J, ULLRICH R, HROMI J et al.: Sildenafil is a pulmonary vasodilator in awake lambs with acute pulmonary hypertension. Anesthesiology (2000) 92(6):1702-1712. (Pubitemid 30412491)
59. YAMAMOTO T, WADA A, TSUTAMOTO T, OHNISHI M, HORIE M: Long-term treatment with a phosphodiesterase type 5 inhibitor improves pulmonary hypertension secondary to heart failure through enhancing the natriuretic peptides-cGMP pathway. J. Cardiovasc. Pharmacol. (2004) 44(5):596-600. (Pubitemid 39441701)
60. ZHAO L, MASON NA, STRANGE JW, WALKER H, WILKINS MR: Beneficial effects of phosphodiesterase 5 inhibition in pulmonary hypertension are influenced by natriuretic peptide activity. Circulation (2003) 107(2):234-237. (Pubitemid 36135217)
61. LEPORE JJ, MAROO A, BIGATELLO LM et al.: Hemodynamic effects of sildenafil in patients with congestive heart failure and pulmonary hypertension: combined administration with inhaled nitric oxide. Chest (2005) 127(5):1647-1653. • Invasive haemodynamic study in patients with heart failure; effects of sildenafil, NO and a combination of the two is examined. (Pubitemid 46218790)
62. ALAEDDINI J, UBER PA, PARK MH et al.: Efficacy and safety of sildenafil in the evaluation of pulmonary hypertension in severe heart failure. Am. J. Cardiol. (2004) 94(11):1475-1477. (Pubitemid 39556232)
63. MAHMUD A, HENNESSY M, FEELY J: Effect of sildenafil on blood pressure and arterial wave reflection in treated hypertensive men. J. Hum. Hypertens. (2001) 15(10):707-713. (Pubitemid 32975870)
64. VLACHOPOULOS C, HIRATA K, O'ROURKE MF: Effect of sildenafil on arterial stiffness and wave reflection. Vasc. Med. (2003) 8(4):243-248. (Pubitemid 38585138)
65. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N. Engl. J. Med. (1991) 325(5):293-302.
66. COHN JN, ARCHIBALD DG, ZIESCHE S et al.: Effect of vasodilator therapy on mortality in chronic congestive heart failure. Results of a Veterans Administration Cooperative Study. N. Engl. J. Med. (1986) 314(24):1547-1552. (Pubitemid 16114684)
67. COHN JN, JOHNSON G, ZIESCHE S et al.: A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N. Engl. J. Med. (1991) 325(5):303-310.
68. COHN JN, TOGNONI G: A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N. Engl. J. Med. (2001) 345(23):1667-1675. (Pubitemid 33126822)
69. TAYLOR AL, ZIESCHE S, YANCY C et al.: Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N. Engl. J. Med. (2004) 351(20):2049-2057. (Pubitemid 39482498)
70. Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group. N. Engl. J. Med. (1987) 316(23):1429-1435. (Pubitemid 17079089)
71. PATEL KN, YAN L, GANDHI A, SCHOLZ PM, WEISS HR: Interaction between the opposing functional effects of cyclic AMP and cyclic GMP in hypertrophic cardiac myocytes. Basic Res. Cardiol. (2001) 96(1):34-41. (Pubitemid 32117761)
72. LOHMANN SM, FISCHMEISTER R, WALTER U: Signal transduction by cGMP in heart. Basic Res. Cardiol. (1991) 86(6):503-514.
73. 2+ current is regulated by cyclic GMP-dependent protein kinase in mammalian cardiac myocytes. Proc. Natl. Acad. Sci. USA (1991) 88(4):1197-1201.
74. 2+ current. Involvement of cGMP-inhibited and cGMP-stimulated phosphodiesterases through guanylyl cyclase activation. J. Biol. Chem. (1993) 268(35):26286-26295.
75. 2+ channel current in human atrial myocytes. J. Physiol. (2001) 533(Part 2):329-340.
76. BEAULIEU P, CARDINAL R, PAGE P, FRANCOEUR F, TREMBLAY J, LAMBERT C: Positive chronotropic and inotropic effects of C-type natriuretic peptide in dogs. Am. J. Physiol. (1997) 273(4 Part 2):H1933-H1940.
77. HIROSE M, FURUKAWA Y, KUROGOUCHI F, NAKAJIMA K, MIYASHITA Y, CHIBA S: C-type natriuretic peptide increases myocardial contractility and sinus rate mediated by guanylyl cyclase-linked natriuretic peptide receptors in isolated, blood-perfused dog heart preparations. J. Pharmacol. Exp. Ther. (1998) 286(1):70-76.
78. WOLLERT KC, YURUKOVA S, KILIC A et al.: Increased effects of C-type natriuretic peptide on contractility and calcium regulation in murine hearts overexpressing cyclic GMP-dependent protein kinase I. Br. J. Pharmacol. (2003) 140(7):1227-1236. (Pubitemid 38117427)
79. LAYLAND J, LI JM, SHAH AM: Role of cyclic GMP-dependent protein kinase in the contractile response to exogenous nitric oxide in rat cardiac myocytes. J. Physiol. (2002) 540(Part 2):457-467. (Pubitemid 35190124)
80. PIERKES M, GAMBARYAN S, BOKNIK P et al.: Increased effects of C-type natriuretic peptide on cardiac ventricular contractility and relaxation in guanylyl cyclase A-deficient mice. Cardiovasc. Res. (2002) 53(4):852-861. (Pubitemid 34261023)
81. VILA-PETROFF MG, YOUNES A, EGAN J, LAKATTA EG, SOLLOTT SJ: Activation of distinct cAMP-dependent and cGMP-dependent pathways by nitric oxide in cardiac myocytes. Circ. Res. (1999) 84(9):1020-1031. (Pubitemid 29227681)
82. WEGENER JW, NAWRATH H, WOLFSGRUBER W et al.: cGMP-dependent protein kinase I mediates the negative inotropic effect of cGMP in the murine myocardium. Circ. Res. (2002) 90(1):18-20. (Pubitemid 34074603)
83. KUHN M: Structure, regulation, and function of mammalian membrane guanylyl cyclase receptors, with a focus on guanylyl cyclase-A. Circ. Res. (2003) 93(8):700-709. (Pubitemid 37288664)
84. PADAYATTI PS, PATTANAIK P, MA X, VAN DEN AKKER F: Structural insights into the regulation and the activation mechanism of mammalian guanylyl cyclases. Pharmacol. Ther. (2004) 104(2):83-99. (Pubitemid 39424255)
85. FIEDLER B, LOHMANN SM, SMOLENSKI A et al.: Inhibition of calcineurin-NFAT hypertrophy signaling by cGMP-dependent protein kinase type I in cardiac myocytes. Proc. Natl. Acad. Sci. USA (2002) 99(17):11363-11368. (Pubitemid 34920931)
86. HASSAN MA, KETAT AF: Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol. (2005) 5(1):10. (Pubitemid 41460676)
87. KISHIMOTO I, ROSSI K, GARBERS DL: A genetic model provides evidence that the receptor for atrial natriuretic peptide (guanylyl cyclase-A) inhibits cardiac ventricular myocyte hypertrophy. Proc. Natl. Acad. Sci. USA (2001) 98(5):2703-2706. (Pubitemid 32209546)
88. KNOWLES JW, ESPOSITO G, MAO L et al.: Pressure-independent enhancement of cardiac hypertrophy in natriuretic peptide receptor A-deficient mice. J. Clin. Invest. (2001) 107(8):975-984. (Pubitemid 32328002)
89. TAKIMOTO E, CHAMPION HC, LI M et al.: Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat. Med. (2005) 11(2):214-222. • Demonstrates a possible beneficial effect of enhanced cGMP-mediated signaling in preventing or reversing myocardial hypertrophy.
90. WOLLERT KC, FIEDLER B, GAMBARYAN S et al.: Gene transfer of cGMP-dependent protein kinase I enhances the antihypertrophic effects of nitric oxide in cardiomyocytes. Hypertension (2002) 39(1):87-92. (Pubitemid 34098094)
91. ZAHABI A, PICARD S, FORTIN N, REUDELHUBER TL, DESCHEPPER CF: Expression of constitutively active guanylate cyclase in cardiomyocytes inhibits the hypertrophic effects of isoproterenol and aortic constriction on mouse hearts. J. Biol. Chem. (2003) 278(48):47694-47699. (Pubitemid 37523215)
92. TAKIMOTO E, CHAMPION HC, BELARDI D et al.: cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ. Res. (2005) 96(1):100-109. (Pubitemid 40095759)
93. DAS A, OCKAILI R, SALLOUM F, KUKREJA RC: Protein kinase C plays an essential role in sildenafil-induced cardioprotection in rabbits. Am. J. Physiol. Heart Circ. Physiol. (2004) 286(4):H1455-H1460. (Pubitemid 38381155)
94. DAS A, XI L, KUKREJA RC: Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J. Biol. Chem. (2005) 280(13):12944-12955. (Pubitemid 40491117)
95. SALLOUM F, YIN C, XI L, KUKREJA RC: Sildenafil induces delayed preconditioning through inducible nitric oxide synthase-dependent pathway in mouse heart. Circ. Res. (2003) 92(6):595-597. (Pubitemid 36417692)
96. FISHER PW, SALLOUM F, DAS A, HYDER H, KUKREJA RC: Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation (2005) 111(13):1601-1610. (Pubitemid 40525159)
97. WALLIS RM, CORBIN JD, FRANCIS SH et al.: Tissue distribution of phosphodiesterase families and the effects of sildenafil on tissue cyclic nucleotides, platelet function, and the contractile responses of trabeculae carneae and aortic rings in vitro. Am. J. Cardiol. (1999) 83(5A):3C-12C. (Pubitemid 29122752)
98. SENZAKI H, SMITH CJ, JUANG GJ et al.: Cardiac phosphodiesterase 5 (cGMP-specific) modulates β-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J. (2001) 15(10):1718-1726. (Pubitemid 32730219)
99. BORLAUG BA, MELENOVSKY V, MARHIN T, FITZGERALD P, KASS DA: Sildenafil inhibits β-adrenergic-stimulated cardiac contractility in humans. Circulation (2005) 112(17):2642-2649. •• PDE5 inhibition shown to alter contractile response of human myocardium to β-adrenergic stimulation.
100. Xamoterol in severe heart failure. The Xamoterol in Severe Heart Failure Study Group. Lancet (1990) 336(8706):1-6.
101. O'CONNOR CM, GATTIS WA, URETSKY BF et al.: Continuous intravenous dobutamine is associated with an increased risk of death in patients with advanced heart failure: insights from the Flolan International Randomized Survival Trial (FIRST). Am. Heart J. (1999) 138(1 Part 1):78-86. (Pubitemid 29331125)
102. OLIVA F, LATINI R, POLITI A et al.: Intermittent 6-month low-dose dobutamine infusion in severe heart failure: DICE multicenter trial. Am. Heart J. (1999) 138(2 Part 1):247-253. (Pubitemid 29379674)
103. MONGILLO M, McSORLEY T, EVELLIN S et al.: Fluorescence resonance energy transfer-based analysis of cAMP dynamics in live neonatal rat cardiac myocytes reveals distinct functions of compartmentalized phosphodiesterases. Circ. Res (2004) 95(1):67-75. •• This study demonstrates the role of individual phosphodiesterases in the compartmentation of cAMP-mediated signaling. (Pubitemid 38931837)
104. MONGILLO M, TOCCHETTI CG, TERRIN A et al.: Compartmentalized phosphodiesterase-2 activity blunts β-adrenergic cardiac inotropy via an NO/cGMP-dependent pathway. Circ. Res. (2005) 98(2):226-234. (Pubitemid 43755354)